Olopatadine HCL 0.1% Ophthalmic Solution

The contract award pertains to the procurement of Olopatadine HCl 0.1% Ophthalmic Solution in 5ML bottles under solicitation SPE2D222R0117, managed by the Defense Logistics Agency Troop Support. The base contract was awarded effective February 15, 2023, with option years extending through February 14, 2027, each covering an annual quantity of 346,879 bottles at a fixed unit price of $10.16, resulting in a base period value of approximately $3.5 million and a potential total contract value of up to $17.6 million if all four option years are exercised. The manufacturer is Apotex Inc., located in Richmond Hill, Ontario, Canada, with delivery terms designated as FOB Destination, meaning the government assumes responsibility upon receipt at the designated U.S. location. Modifications have been issued to update the manufacturer, place of performance, and National Drug Code (NDC), revise pricing and shipment dates, exercise each option year in sequence, and incorporate critical regulatory clauses including the Drug Supply Chain Security Act, Federal Acquisition Supply Chain Security Act, and prohibitions against ByteDance-covered applications and certain telecommunications equipment. Packaging and labeling requirements mandate bar code compliance with GSI-128 or HIBC standards, encoding NDC, lot number, and expiration date with ANSI/ISO/IEC quality grade C or better, consistent with DSCSA traceability mandates. The contract includes clauses mandating cybersecurity protections, paid sick leave, minimum wage compliance, employment verification, electronic invoicing via governmentwide purchase card, and reporting obligations such as executive compensation disclosures and small business subcontracting plans. The Contracting Officer is Jason Wray, with Kyle Lewicki as the primary point of contact, and no Contracting Officer’s Representative is listed. The contract is treated as a commercial item acquisition under FAR Part 12, with no identified small business set-aside status, though affirmative representations trigger reporting under multiple federal mandates including VETS-4212 for veterans employment and FFATA for subcontract disclosures.